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Abstract 
Background: Clinical significance of germinal center B-cell (GCB) and non-GCB sub-categorization, expression of MYC, 
BCL2, BCL6, CD5 proteins and Epstein Barr virus encoded RNA (EBER) positivity in diffuse large B-cell lymphoma (DLBCL) 
remain controversial. Could these biomarkers accurately identify high risk DLBCL patients? Are MYC, BCL2 and BCL6 
proteins expression feasible as baseline testing to predict c-Myc, BCL2 or BCL6 gene rearrangements?  
Aims: To investigate prognostic values of GCB/non-GCB sub-categorization, Double Protein Expression Lymphoma (DPL), 
Triple Protein Expression Lymphoma (TPL), positivity of CD5 protein and EBER in patients with DLBCL disease. To evaluate 
correlation between BCL2 , c-Myc and BCL6 gene rearrangements with BCL2, MYC and BCL6 proteins expression. 
Methods: Diagnostic tissue samples of 120 DLBCL patients between January 2012 to December 2013 from four major 
hospitals in Malaysia were selected. Samples were subjected to immunohistochemical staining, fluorescent in-situ 
hybridization (FISH) testing, and central pathological review. Pathological data were correlated with clinical characteristics 
and treatment outcome. 
Results: A total of 120 cases were analysed. Mean age of diagnosis was 54.1 years ± 14.6, 64 were males, 56 were females, 
mean follow up period was 25 months (ranged from 1 to 36 months). Of the 120 cases, 74.2% were non-GCB whereas 25.8% 
were GCB, 6.7% were EBER positive, 6.7% expressed CD5 protein, 13.3% were DPL and 40% were TPL. The prevalence of 
c-Myc, BCL2, BCL6 gene rearrangements were 5.8%, 5.8%, and 14.2%, respectively; and 1.6% were Double Hit Lymphoma 
(DHL). EBER positivity, DPL, TPL, c-Myc gene rearrangement, BCL2 gene rearrangement, extra copies of BCL2 gene and BCL6 
gene rearrangement were associated with shorter median overall survival (P<0.05). IPI score was the significant determinants 
of median overall survival in DPL and TPL (P<0.05). CD5 protein expression and GCB/non-GCB sub-categorization did not 
affect treatment outcome (P>0.05). Overall, c-Myc, BCL2 and BCL6 gene rearrangements showed weak correlation with 
expression of MYC, BCL2 and BCL6 proteins (P>0.05). Fluorescent in situ hybridization is the preferred technique for 
prediction of treatment outcome in DLBCL patients.  
Conclusion: c-Myc, BCL2, and BCL6 gene rearrangements, EBER expression, DHL, TPL and IPI score are reliable risk 
stratification tools. MYC, BCL2 and BCL6 proteins expression are not applicable as baseline biomarkers to predict c-Myc, 
BCL2, and BCL6 gene rearrangements. 
Key words: diffuse large B-cell lymphoma, c-Myc, BCL2 and BCL6 gene rearrangements, diffuse large B-cell lymphoma with CD5 protein expression, 
diffuse large B-cell lymphoma with positive EBER expression, non-germinal center B-cell subtype, Asia  
 
Ivyspring  
International Publisher 
